Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Ainos, Inc.

NASDAQ: AIMD · Technology · 3 alerts · CIK 1014763

Share price
$1.14Close, Nov 16
Market cap
$8.62M
Shares outstanding
7.57MLatest SEC cover page
Sector
Technology
Industry
Computer Peripheral Equipment, NECSIC 3577

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Ainos, Inc. filings on SEC EDGAR ↗

8:31 AM ET 8-K
Contract Win

Ainos Wins $9M Contract from ASE Technology Holding Co., Ltd.

Ainos, Inc. signed a $9 million purchase agreement with ASE Technology Holding Co., Ltd. for 5,000 units of its AI NOSE equipment, marking the largest order in the company's history. ASE will pay a 50% deposit ($4.5 million) within 60 days, with the remaining balance due upon delivery completion. The agreement also includes ongoing annual maintenance fees for platform usage and technical updates.

Value
$9M
Counterparty
ASE Technology Holding Co., Ltd.
8:42 AM ET 8-K
Financial Results

Ainos Financial Results

Ainos reported Q3 2026 financial results with revenue increasing significantly to $642,889, driven by VELDONA licensing and AI Nose semiconductor programs. The company narrowed its GAAP net loss by 36% year-over-year and highlighted a subsequent $9 million follow-on order for its AI Nose systems.

“Our third-quarter results show progress in translating commercial agreements into revenue. Revenue reached $642,889, up 29,567% year over year, driven by VELDONA licensing and our AI Nose semiconductor program. We delivered 1,400 AI Nose systems under our initial $2.1 million agreement and received initial orders from another semiconductor customer.”

Eddy Tsai, Chairman, President and Chief Executive Officer

“Our Q3 2026 results demonstrate progress in both revenue generation and operating discipline. GAAP net loss improved 36% year over year while non-GAAP adjusted net loss improved 51%. GAAP gross margin increased to 83.4% from 78.0% in the third quarter of 2025, while non-GAAP gross margin increased to 83.6% from 78.0%, excluding share-based compensation and depreciation and amortization allocated to cost of revenue.”

Christopher Lee, Chief Financial Officer of Ainos
8:02 AM ET 8-K
Licensing Deal

Ainos Licensing Deal with BioPhoenix Co., Ltd. Worth $10M

Ainos entered into a global exclusive license agreement with BioPhoenix for its VELDONA low-dose oral interferon alpha technology platform for Sjögren’s Disease and Thrombocytopenia. Ainos will receive an upfront fee of $600,000 and is eligible for up to $10.0 million in total fees if additional indications are licensed, plus 25% of net sublicensing revenue. BioPhoenix will assume all clinical and regulatory funding and execution for the licensed indications.

Value
$10M
Counterparty
BioPhoenix Co., Ltd.
Term
20 years

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.